CV Sciences, Inc. (CVSI): debt financing — CV Sciences restructures notes: adds conversion at $0.06/share, principal to $2.256M

CV Sciences, Inc.

Outstanding note principal increased 20% to $2,256,000; monthly redemption obligation eliminated.
Added conversion feature at $0.06/share, initially convertible into 37.6M shares of common stock.
True-up provision requires additional note if net proceeds from conversion sales fall short of principal.
Company paid $15,000 documentation fee; beneficial ownership cap set at 4.99% (can be raised to 9.99%).
Management says restructuring strengthens balance sheet and positions for sustained profitability.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CV Sciences, Inc. amended convertible notes of aggregate outstanding principal amount of $2,256,000 with institutional investor.

Instrument: convertible notes
Principal: aggregate outstanding principal amount of $2,256,000
Counterparty: institutional investor
Event: amendment

Exact text from the filing

amounts of the Amended Notes were increased by 20% under the terms of the Notes. After such adjustment, the Amended Notes have an aggregate outstanding principal amount of $2,256,000. • True-Up Provision. The Amended Notes include a true-up provision designed to ensure that the net proceeds received by the Investor upon conversion and sale of the conversion

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

CV Sciences, Inc. issued convertible note to institutional investor for $2,256,000 aggregate outstanding principal amount.

Security: convertible note
Purchaser: institutional investor
Consideration: $2,256,000 aggregate outstanding principal amount

Exact text from the filing

amounts of the Amended Notes were increased by 20% under the terms of the Notes. After such adjustment, the Amended Notes have an aggregate outstanding principal amount of $2,256,000. • True-Up Provision. The Amended Notes include a true-up provision designed to ensure that the net proceeds received by the Investor upon conversion and sale of the conversion

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.7

CV Sciences, Inc. issued convertible note to institutional investor.

Security: convertible note
Purchaser: institutional investor

Exact text from the filing

the Company will issue a new senior secured convertible note on substantially the same terms and conditions of the Amended Notes (the “Third Note”) with a principal amount equal to the aggregate shortfall in excess of $94,000

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CV Sciences, Inc. amended Agreement with an institutional investor ("Investor") valued at aggregate outstanding principal amount of $2,256,000 (effective 2026-03-04).

Action: amendment
Agreement: credit facility
Counterparty: an institutional investor ("Investor")
Value: aggregate outstanding principal amount of $2,256,000
Effective: 2026-03-04

Exact text from the filing

On March 4, 2026, the Company and the Investor entered into an agreement (the “Agreement”) to, among other things, amend and restate the Amended Original Note and the Second Note

View on SEC.gov

35 debt financings filed in the last 30 days. Browse all debt financings →

CV Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-100436

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.